Industry News (Candidiasis)

Anti-Fungal Technology May Promote Vaccine Development Against Candida albicans

Published in Vaccine Weekly, June 28th, 1999

Inhibitex, Inc., Alpharetta, Georgia, has signed an exclusive licensing agreement with the University of Minnesota for proprietary MSCRAMM surface proteins from Candida albicans that may be useful in the development of vaccines used in preventing fungal infections caused by this organism.

The technology licensed by Inhibitex is based upon research conducted by Margaret Hostetter, MD, while at the University of Minnesota, Department of Pediatric Infectious Diseases. Based upon the discoveries of Hostetter, Inhibitex expects to develop a vaccine that will eliminate or reduce the number of C. albicans organisms present within high-risk individuals. The...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1999-06-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry